ADMA Biologics Inc (NASDAQ:ADMA) posted its earnings results on Friday. The biotechnology company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.29, Bloomberg Earnings reports. The business had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $3.52 million.

ADMA Biologics (NASDAQ:ADMA) traded up 1.03% during mid-day trading on Friday, hitting $2.94. 36,784 shares of the company’s stock were exchanged. ADMA Biologics has a 12 month low of $2.76 and a 12 month high of $7.70. The stock’s market cap is $37.88 million. The stock’s 50 day moving average price is $3.47 and its 200-day moving average price is $4.19.

A number of analysts have weighed in on ADMA shares. Maxim Group set a $13.00 target price on shares of ADMA Biologics and gave the stock a “buy” rating in a research note on Monday, May 15th. ValuEngine cut shares of ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

TRADEMARK VIOLATION WARNING: This story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at https://www.thecerbatgem.com/2017/08/12/adma-biologics-inc-nasdaqadma-releases-earnings-results.html.

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Earnings History for ADMA Biologics (NASDAQ:ADMA)

Receive News & Stock Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related stocks with our FREE daily email newsletter.